A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

R.L Coleman,M.F Brady,T.J Herzog,P Sabbatini,D.K Armstrong,J.L Walker,B.G Kim,K Fujiwara,K.S Tewari,D.M O'Malley

doi:10.1016/j.ygyno.2015.01.005

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

R.L Coleman, M.F Brady + Show 8 more

https://doi.org/10.1016/j.ygyno.2015.01.005

Copy DOI

Journal: Gynecologic Oncology	Publication Date: Apr 1, 2015
Citations: 30

Affiliation: The University of Texas MD Anderson Cancer Center, Saitama Medical University, Memorial Sloan Kettering Cancer Center, James Cancer Hospital, Sungkyunkwan University

#Secondary Cytoreductive Surgery #Fallopian Tube Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

Full Text